Beacon's Gene Therapy for X-Linked Retinitis Pigmentosa Succeeds in a Pivotal Trial
On September 21, 2026, Beacon Therapeutics announced that its gene therapy laru-zova met the primary goal of the pivotal VISTA trial in X-linked retinitis pigmentosa (XLRP). It is the first gene therapy for XLRP to succeed in a late-stage trial, and Beacon now plans to ask regulators for approval.
The result matters even more because of what came before it. In 2025, a competing XLRP gene therapy from Johnson & Johnson and MeiraGTx failed its own Phase 3 trial.
What is X-linked retinitis pigmentosa?
Retinitis pigmentosa is a group of inherited diseases in which the light-sensing photoreceptors of the retina slowly die. XLRP is one of the most severe forms. Most cases are caused by mutations in the RPGR gene on the X chromosome.
RPGR makes a protein that works in the connecting cilium, a narrow structure that moves proteins into the part of the photoreceptor that captures light. Without working RPGR, rod cells fail first, causing night blindness in childhood. Cone cells follow, and vision narrows into a tunnel. Many patients are legally blind by middle age.
Because the gene is on the X chromosome, the disease mainly affects boys and men. There is no approved treatment. Luxturna, the first approved gene therapy for an inherited retinal disease, works only for mutations in a different gene, RPE65.
How laru-zova works
Laru-zova (laruparetigene zovaparvovec, formerly AGTC-501) is an AAV vector that carries a full-length, working copy of the RPGR gene. A surgeon injects it under the retina in a single procedure, where it reaches the remaining photoreceptors. The treated cells can then make normal RPGR protein.
The goal is to protect the photoreceptors that are still alive and improve how well they work. A gene therapy cannot bring back cells that have already died, so earlier treatment is likely to help more. For a beginner-friendly look at how AAV gene therapies like this one are designed and delivered, see my book The Life-Changing Power of Gene Therapy.
What the VISTA trial showed
VISTA enrolled 85 males aged 12 to 48 with XLRP caused by RPGR mutations. Patients received a high dose, a low dose, or no treatment as a control group.
The primary endpoint was the share of patients whose low-luminance visual acuity improved by at least 15 letters on a standard eye chart after 12 months. Low-luminance testing checks reading vision in dim light, which is where XLRP patients struggle first. A 15-letter gain equals three full lines on the chart.
High dose: 31.0% of patients gained 15 or more letters (p = 0.0019).
Low dose: 24.1% of patients gained 15 or more letters (p = 0.0106).
Untreated control: 0%.
Both doses beat the control group by a statistically significant margin, and the higher dose produced the larger effect. These results build on Beacon's earlier DAWN Phase 2 study, which had also shown improvements.
Safety
Most side effects were mild to moderate and involved the eye.
Treatment-related side effects occurred in 25% of high-dose patients and 38% of low-dose patients.
Two serious side effects in the low-dose group were attributed to the surgical procedure, not the gene therapy itself.
Subretinal surgery always carries some risk, so these numbers will be watched closely as more patients reach longer follow-up.
Why this win stands out
XLRP has been a hard target. In 2025, J&J and MeiraGTx's bota-vec, another RPGR gene therapy, missed its main goal in the Phase 3 LUMEOS trial. That failure raised doubts about whether gene therapy could produce a clear benefit in this disease.
VISTA's clean result, with zero responders in the control arm, answers that doubt for laru-zova. Regulators already gave the program support: it holds RMAT and Fast Track designations from the FDA, PRIME status from the European Medicines Agency, a UK ILAP designation, and orphan drug status in the US and EU.
What happens next
Beacon plans to meet with regulators for pre-submission talks and to start a rolling Biologics License Application later in 2026. A rolling submission lets a company send completed sections of its application to the FDA as they are ready, rather than all at once.
If approved, laru-zova would be the first treatment of any kind for XLRP.
The bottom line
One injection under the retina gave about a third of high-dose patients a three-line gain in dim-light vision, while no untreated patient improved that much. After a high-profile failure in the same disease, VISTA shows that RPGR gene therapy can work in a pivotal trial. The next test is the FDA review.
Watch the Short: Beacon's XLRP gene therapy explained in under 30 seconds on Gene Tech Times Academy
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
— T.N., Gene Tech Times
Sources: BioPharm International · Ophthalmology Times · pharmaphorum
Comments